Browse drugs

…city, with G3/4 events reported in 22% compared with 14% in the nivolumab monotherapy arm. An update presented at the European Society of…

…en of nausea and vomiting was reported in patients treated with ipilimumab. 55From patient selection to TIL expansion: a comprehensive ove…

…umab) are often used in ovarian and cervical cancers. ICIs (eg, pembrolizumab) are effective in mismatch repair-deficient endometrial cancer …

…responses were associated with favorable clinical outcomes with ipilimumab.4 Tertiary lymphoid structures (TLS) are aggregates of T cells,…

…minantly stereotactic radiosurgery (SRS)) followed by continued osimertinib, with encouraging PFS/OS and acceptable toxicity. By contrast, …

…mab in safety run-in cohorts, 26 patients received rhIL-15 with nivolumab plus ipilimumab. The most common cancer types were gastrointest…

…ortal outcome) as a suspected ADR of different ICIs (nivolumab, pembrolizumab and nivolumab+ipilimumab) within 2 months in the regional Pharm…

…histology-specific platinum doublet chemotherapy, combined with ipilimumab (1 mg/kg every 6 weeks) and nivolumab (360 mg every 3 weeks), f…

…up, with overall survival ranging from 48.8 to 85.4 months from nivolumab initiation. Of the six patients who resumed treatment, only one…

…everity, and management of irAEs in melanoma patients receiving ipilimumab–nivolumab therapy.Material and Methods A retrospective observat…

…horter PFS among patients with metastatic ccRCC treated with 1L nivolumab+ipilimumab. These findings support the concept that host body c…

…rs.Methods DART is a multicenter, multicohort phase II trial of ipilimumab (1 mg/kg intravenously every 6 weeks) plus nivolumab (240 mg in…